Buserelin aniMedica is considered relevant for therapeutic applications that support the management of fertility and the correction of reproductive disorders in designated species, including cattle, horses, and rabbits. This therapeutic scope is considered relevant for maintaining reproductive health and rhythm.

The primary use is applied across domains where additional symptomatic support is needed for symptoms that create noticeable physiological strain by disrupting optimal timing and rhythm. Key therapeutic areas involve managing ovarian pathologies, such as follicular cysts in cattle; intervening in cases of absent or irregular reproductive cycles (anestrus); and achieving the precise timing of ovulation for breeding. By addressing these issues, the medication contributes to easing the overall symptom load associated with unpredictable timing and may assist with maintaining functional stability within breeding programs.

---

Quick Fact: Relief for Reproductive Cycle Irregularities The medication is commonly used to help manage conditions presenting with acute or disruptive symptom patterns of ovarian origin, providing supportive relief that assists with maintaining functional stability.

Regulatory References

1. UK Veterinary Medicines Directorate (VMD) product information

Eligibility Map: Who can and cannot use Buserelin aniMedica

The eligibility for Buserelin aniMedica is strictly defined by regulatory documents, focusing on the authorized animal species and physiological state.

Populations for whom use is allowed (as stated in label):

• Cattle (Cows, Heifers)
• Horses (Mares)
• Rabbits (Adult females for reproduction)

---

Populations for whom use is contraindicated:

• Animals with Known Hypersensitivity: Prohibited in animals with a known hypersensitivity to the active substance, Buserelin, or to any of the excipients, such as Benzyl alcohol.
• Non-Target Species: Prohibited for use in any species other than Cattle, Horses, and Rabbits.
• Human Pregnant Women (Administration): The product must not be administered by pregnant women, as Buserelin has demonstrated foetotoxic effects in laboratory animals.

---

Pregnancy and Lactation Eligibility Status (Target Species):

• Pregnancy: Use is not recommended during pregnancy; it is intended for use prior to mating or artificial insemination.
• Lactation: Use is generally permitted during lactation in cattle and horses.

---

Eligibility-Related Restrictions:

• Suboptimal Cattle: Use may be associated with suboptimal results in cows with a low Body Condition Score or a short interval between calving and insemination.
• Human Administration: Women of child-bearing age should administer the product with caution due to the potential for GnRH analogue absorption through the skin.

The regulatory documents strictly define eligibility based on the authorized target animal species and specific physiological status, which are Cattle, Horses, and Rabbits for reproductive management. Absolute non-eligibility is established by a formal contraindication for known hypersensitivity to the drug components. Conditional or restricted use is imposed when the animal's health status may interfere with optimal outcomes, and explicit warnings govern the eligibility of human handlers.

The official regulatory profile for the veterinary medicinal product Buserelin aniMedica is primarily characterized by specific administration constraints rather than documented drug–drug interactions. Regulatory product information, such as the Summary of Product Characteristics from national veterinary authorities, indicates that no adverse interactions with other medicinal products are known based on the available data. The absence of documented interactions means the official focus is on ensuring correct preparation and handling.

A mandatory restriction listed in regulatory documents is classified as a Major Incompatibility. Due to a lack of compatibility studies, the Buserelin aniMedica solution for injection must not be mixed with any other veterinary medicinal products. This procedural constraint prohibits the simultaneous physical co-administration of Buserelin in the same syringe or delivery system.

A further specific constraint relates to non-medicinal substances. Official documentation states that the product's pharmacological effect may be negatively influenced by the presence of residues of alcohol and disinfectants. This requires careful procedural adherence during preparation and injection to prevent the attenuation of the Buserelin effect. The overall interaction structure is thus defined by these procedural constraints and the absence of established pharmacokinetic or pharmacodynamic interactions with other medicines.

Buserelin aniMedica is a synthetic analogue of gonadotropin-releasing hormone (GnRH). Buserelin acts as an agonist by binding to GnRH receptors located on the anterior pituitary gland. Due to its continued presence and sustained concentration, this initial agonistic interaction stimulates the pituitary gland, resulting in a temporary surge in the production and release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

However, the constant stimulation leads to a cascade of events involving the desensitization and subsequent down-regulation of the GnRH receptors. This receptor loss effectively shuts down the pituitary's response mechanism. The desensitization results in a prolonged and consistent suppression of both LH and FSH synthesis and secretion. The resulting sustained low levels of circulating gonadotropins modulate the activity of the gonads, leading to a profound reduction in the production of sex hormones, such as testosterone and estrogen. This systemic reduction in hormonal stimulus results in a reduction in hormone-dependent cell proliferation.

Buserelin aniMedica is formulated as a ready-to-use solution for injection containing 0.004 mg of Buserelin per ml. Its administration follows high-precision, event-based protocols. Systemic delivery is performed via the intramuscular (IM), intravenous (IV), or subcutaneous (SC) routes, with the intramuscular route being generally preferred. The administration must always follow an aseptic procedure.

The dosing is strictly dependent on the target species and the specific reproductive goal, with treatment typically administered as a single injection tied to a critical reproductive event.

Target Species	General Principle of Use	Dose of Buserelin (mu g)	Frequency
Cattle (Cows)	Follicular cysts or oestrus induction	20 mu g	Single treatment
Cattle (Cows)	Improving conception rate at AI	10 mu g	Single treatment
Horses (Mares)	Induction of ovulation	40 mu g	Single treatment (repeatable in 24h)
Rabbits	Improving conception rate at mating	0.8 mu g	Single treatment

These regimens are applied with precise timing: for conception rate improvement in cattle and rabbits, the dose is given at the time of mating or artificial insemination. In mares, the injection for ovulation induction is ideally given approximately six hours prior to service. The medicine is also used as part of cyclic synchronization programs in cattle, involving two 10 µg injections separated by a prostaglandin treatment. For multi-dose containers, a restriction is placed on the number of times the vial can be pierced to help maintain sterility.

Research evidence / Overview of studies for Buserelin aniMedica

---

Evidence for use in Endometriosis and Uterine Fibroids

Research has explored the patterns observed when Buserelin aniMedica was evaluated for conditions associated with endometriosis and certain benign conditions of the uterus, like uterine fibroids. The research in this area includes studies that monitored outcomes related to short-term changes in symptoms.

In these studies, the drug was evaluated in women with conditions characterized by functional limitations and outcomes related to physical discomfort. Research highlights that findings were related to the measurement of fibroid size and monitoring of outcomes describing perceived discomfort or activity level associated with endometriosis. However, the evidence derived from these settings often focuses on short-term or episodic symptom patterns, and follow-up durations were limited.

---

Evidence for use in Prostate Cancer

Buserelin aniMedica was studied for its use in patients with advanced prostate cancer. The research in this area involves studies examining temporary physiological imbalance that were conducted during the course of the disease.

Studies monitored patient-reported outcomes describing perceived discomfort and outcomes related to systemic or functional imbalance. Research highlights changes measured during the study period, particularly regarding certain hormones linked to the disease. The data show patterns related to how these markers evolved in the observed populations.

---

Evidence for use in Assisted Reproduction (e.g., in vitro fertilization)

Buserelin aniMedica was evaluated in research contexts as part of protocols for assisted reproduction, such as in vitro fertilization (IVF). The research explored the use of the drug in relation to the timing of the menstrual cycle, which is relevant in trials assessing short-term or episodic changes in this context.

Research highlights the patterns observed during the study period regarding ovarian response and the timing of egg release. Evidence derived from studies was from settings with varying challenges related to fertility treatment. Findings were mixed in some studies, and results apply only to the populations studied under the specific conditions under which the research was conducted.

---

What is still uncertain about Buserelin aniMedica

Research provides context but highlights several areas of uncertainty. Findings were mixed or inconsistent across different studies for certain outcomes. The evidence quality varies, and data for certain groups remain insufficient.

The long-term effects are not fully established, and the evidence does not determine whether an individual will respond similarly, as study results reflect group patterns under specific conditions.

Key Studies & References

1. Study Details | NCT00002633 | Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer | ClinicalTrials.gov

Common questions about Buserelin aniMedica (FAQ)

Q: What is the main reason doctors prescribe Buserelin aniMedica?

Buserelin aniMedica is an authorized veterinary medicine used by veterinarians to manage reproductive cycles in animals like cattle, horses, and rabbits. The active substance, Buserelin, is also used in human medicine to treat hormone-dependent conditions such as prostate cancer, endometriosis, and as part of assisted reproduction protocols.

Q: Is Buserelin aniMedica used for the same things as other medicines ending in '-relin'?

Buserelin aniMedica belongs to the pharmacological class known as GnRH analogues, which are designed to influence the body's natural reproductive hormone system. While all medicines in this class generally target the same fundamental pathway, they are approved for different specific indications and may have different formulations.

Q: How does the effect of Buserelin aniMedica start or wear off?

Buserelin is rapidly cleared from the bloodstream after administration. Its intended action is to cause a prolonged suppression of reproductive hormones by desensitizing receptors in the pituitary gland. Official information suggests this hormonal effect is generally reversible after stopping treatment, though the specific timeframe for the full return of hormone function may vary.

Q: Is it common to feel a brief increase in symptoms when first starting Buserelin aniMedica?

Official documentation for the veterinary product Buserelin aniMedica reports no adverse reactions in the target animal species. However, when the active substance Buserelin is used in humans for certain conditions, the initial surge in hormones may potentially lead to a temporary worsening of symptoms in the first few weeks, often referred to as a tumour flare reaction.

Q: Are there any common supplements or vitamins that might interact with Buserelin aniMedica?

Official veterinary product information does not list interactions with supplements. However, human patient information for Buserelin advises discussing all drugs, natural products, and vitamins with a healthcare provider before starting treatment.

Q: Will I need ongoing monitoring or tests while using Buserelin aniMedica?

While specific monitoring is not detailed on the veterinary label, human regulatory documents often require regular monitoring of patient progress, hormone levels, and liver enzymes. Patients with certain pre-existing conditions are also advised to be monitored carefully during treatment.

Q: Does Buserelin aniMedica affect my ability to drive or use machinery?

Regulatory documents for human Buserelin state that it may cause side effects like dizziness or tiredness, which can affect concentration and reaction time. Caution should be exercised, and driving or operating machinery should be avoided if you are experiencing these symptoms.

Q: I heard this type of medicine can cause bone changes. Is that something to be concerned about with Buserelin aniMedica?

The official safety data for the veterinary product Buserelin aniMedica lists no adverse reactions. Nevertheless, human regulatory information for Buserelin warns that long-term use can be associated with a risk of decreased bone mineral density, an effect that is generally reversible after stopping treatment.

Q: What is the time frame for expecting to notice the main effects of Buserelin aniMedica?

For its use in reproductive timing in animals, the product is designed to induce a hormone surge that starts within hours of administration. For therapeutic hormone suppression in human-related conditions, it usually requires a period of consistent use for the full intended effects to be achieved.

Q: If I miss a dose of Buserelin aniMedica, what does the official information say?

Official human patient information indicates that a missed dose may be taken as soon as it is remembered, unless it is nearly time for the next scheduled dose. Patients are cautioned against taking a double dose to compensate for a forgotten one.

Q: Are the side effects of Buserelin aniMedica the same for men and women?

The safety profile for the active ingredient Buserelin differs between the sexes when used in humans. For example, women may experience effects similar to menopausal symptoms, while men may experience symptoms related to the treatment of their underlying condition.

Q: What official resources (like government websites) provide information about Buserelin aniMedica?

The most detailed official information is provided by national regulatory bodies such as the UK Veterinary Medicines Directorate (VMD), the European Medicines Agency (EMA), and local government health authorities that publish the Summary of Product Characteristics (SmPC).

Q: Can a person with diabetes use Buserelin aniMedica?

Human regulatory documents suggest that patients with pre-existing diabetes should be carefully monitored. This monitoring may involve checking glucose levels more regularly during the course of treatment.

Q: Is it possible for Buserelin aniMedica to be ineffective for some people?

Official veterinary documents state that treatment with a GnRH analogue is only symptomatic and does not eliminate the underlying cause of a fertility disorder. They also note that suboptimal results may occur in cattle with a negative energy balance or low body condition score.

Q: What information is provided about Buserelin aniMedica and pre-existing heart conditions?

Human use of Buserelin has been associated with a potential risk of cardiovascular issues, including increased blood pressure or heart rhythm problems. Patients with pre-existing heart conditions may require close monitoring.

Q: Can I use Buserelin aniMedica if I am allergic to similar medications?

Buserelin aniMedica is officially contraindicated in animals with known hypersensitivity to the active substance, Buserelin, or any of its inactive ingredients. If you have an allergy to similar GnRH analogue medications, you should discuss this with a professional prior to use.

Q: What should a patient do if they accidentally use more Buserelin aniMedica than prescribed?

In case of accidental overdose, the official documents advise that immediate medical attention should be sought. Potential symptoms of overdose may include weakness, nervousness, dizziness, headache, or hot flushes.

Q: What is the difference between the short-term and long-term use of Buserelin aniMedica?

The veterinary use of Buserelin aniMedica is typically short-term and event-based, often involving a single dose or repeated doses over only a few days. In contrast, Buserelin may be used long-term for human conditions, where risks such as decreased bone density are of greater concern and require specific monitoring.

Q: Will I experience changes in my menstrual cycle while on Buserelin aniMedica?

When used in women, the drug is designed to suppress the reproductive axis, meaning significant hormonal changes are expected. This suppression of the reproductive axis may lead to changes in the menstrual cycle, including the temporary stopping of the cycle.

Q: Does Buserelin aniMedica interfere with routine blood tests?

Yes, Buserelin may affect the results of some blood tests, particularly those measuring liver enzymes and blood fats (lipids). Official information suggests that providers should be informed if a patient is undergoing blood tests while on this treatment.

Q: What if I have kidney or liver problems? Does that change who can use Buserelin aniMedica?

Buserelin is broken down and eliminated by the liver and kidneys. While the veterinary label does not detail specific restrictions, human regulatory documents note that closer monitoring may be necessary for patients with existing problems in these organs, as the drug is broken down by the liver and kidneys.

Q: Is Buserelin aniMedica considered a high-risk medication by regulatory bodies?

For the target animal species, the product has a favorable safety profile with no adverse reactions. However, the label contains specific special handling warnings for human administrators, particularly women of child-bearing age, due to the hormonal action of GnRH analogues.

Q: What specific type of specialist typically prescribes Buserelin aniMedica?

Buserelin aniMedica is a veterinary medicinal product and is prescribed and administered by a veterinarian or a qualified professional under their direction. This typically occurs in a farm or clinical setting for herd management or reproductive health purposes.

Q: How long after stopping Buserelin aniMedica do its effects typically clear from the body?

Buserelin is rapidly cleared from the bloodstream after administration. Its intended action is to cause a prolonged suppression of reproductive hormones by desensitizing receptors in the pituitary gland. Official information suggests this hormonal effect is generally reversible after stopping treatment, though the specific timeframe for the full return of hormone function may vary.

Q: Are there any foods or drinks that should be avoided when using Buserelin aniMedica?

While no specific foods are officially listed as interacting with Buserelin, some human patient information advises that avoiding alcohol, spicy food, and caffeine may help in managing common side effects like hot flashes.

Q: Has Buserelin aniMedica been studied in adolescents or children?

For human use, Buserelin is contraindicated in newborns and infants because the formulation contains benzyl alcohol. While the active substance is sometimes used in adolescents for certain conditions in some regions, this is not an authorized use detailed on the product information for Buserelin aniMedica.

Q: What is the official information regarding Buserelin aniMedica and mental health conditions?

Human regulatory documents indicate that patients with a history of depression may require careful monitoring and treatment, if necessary, during the course of Buserelin treatment. This is due to the risk of recurrence or worsening of the condition.

Q: Is this drug approved in major regions like the US (FDA) and Europe (EMA)?

The active substance, Buserelin, is approved and marketed widely, including in countries under the European Medicines Agency (EMA). However, the substance is not available in the United States (FDA) for human use.

Storage Conditions and Shelf-Life

Buserelin aniMedica (solution for injection) must be stored at a temperature not exceeding 25°C and should be kept in the outer carton to protect from light.

To ensure safety, the medication must be kept out of the sight and reach of children.

The initial shelf-life of the product as packaged for sale is two years. Once the immediate packaging is first opened, the solution has a reduced in-use stability, and the remaining product must be used within 28 days.

Disposal Requirements

Official regulatory documents state that this medicine must not be disposed of via wastewater or household waste.

Any unused or expired product must be disposed of in accordance with local requirements, typically through authorized take-back schemes or national collection systems for veterinary medicinal products.